Keeping Track: Quick Trips From Breakthrough Designation To Market
Executive Summary
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
You may also be interested in...
Keeping Track: Targeted Oncologics Take Center Stage, Led By Retevmo And Tabrecta Approvals
The latest oncology news and highlights from the Pink Sheet’s FDA Performance Tracker.
Novartis’s Capmatinib Shows High Response Rates In NSCLC
The MET inhibitor already pending US FDA approval had good results in patients with brain metastases. Spectrum’s TKI inhibitor poziotinib continues to be studied after Cohort 1 failure.
Keeping Track: Year-End Submissions Rush Brings Seven Novel Agents To US FDA
Highlights of year-end application submissions including candidates from AstraZeneca, BioMarin, Lilly, MorphoSys, and Seattle Genetics.